The Medical Letter on Drugs and Therapeutics
FROM
ISSUE 1559
ISSUE 1559
November 5, 2018
Issue 1559
- Fremanezumab (Ajovy) and Galcanezumab (Emgality) for Migraine Prevention
- Plazomicin (Zemdri) - A New Aminoglycoside Antibiotic
- Cannabidiol (Epidiolex) for Epilepsy
- In Brief: Acalabrutinib (Calquence) for Mantle Cell Lymphoma (online only)
- In Brief: Brentuximab Vedotin (Adcetris) for Classical Hodgkin's Lymphoma (online only)
| The full issue is available to subscribers | Subscriber Login |
Fremanezumab (Ajovy) and Galcanezumab (Emgality) for Migraine Prevention
November 5, 2018 (Issue: 1559)
The FDA has approved two subcutaneously injected calcitonin gene-related peptide (CGRP) antagonists, fremanezumab-vfrm (Ajovy – Teva) and galcanezumab-gnlm (Emgality – Lilly), for migraine prevention in adults. Fremanezumab and galcanezumab are the second and third subcutaneously injected monoclonal antibodies that target the CGRP pathway to be approved by the FDA for this indication; erenumab-aooe (Aimovig), which targets the CGRP receptor, was the first.1
MIGRAINE PREVENTION — Patients with frequent or severe migraine headaches and those who cannot take or do not have an adequate response to acute treatment are candidates for preventive treatment.2,3
Beta blockers and the antiepileptic drugs valproate (Depakote, and others) and topiramate (Topamax, and generics) are commonly used for
... more- Erenumab (Aimovig) for migraine prevention. Med Lett Drugs Ther 2018; 60:101.
- SD Silberstein et al. Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology 2012; 78:1337.
- E Loder et al. The 2012 AHS/AAN guidelines for prevention of episodic migraine: a summary and comparison with other recent clinical practice guidelines. Headache 2012; 52:930.
- Drugs for migraine. Med Lett Drugs Ther 2017; 59:27.
- U Reuter et al. Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study. Lancet 2018 October 22 (epub).
- ME Bigal et al. Calcitonin gene-related peptide (CGRP) and migraine current understanding and state of development. Headache 2013; 53:1230.
- DW Dodick et al. Effect of fremanezumab compared with placebo for prevention of episodic migraine: a randomized clinical trial. JAMA 2018; 319:1999.
- SD Silberstein et al. Fremanezumab for the preventive treatment of chronic migraine. N Engl J Med 2017; 377:2113.
- VL Stauffer et al. Evaluation of galcanezumab for the prevention of episodic migraine: the EVOLVE-1 randomized clinical trial. JAMA Neurol 2018; 75:1080.
- V Skljarevski et al. Efficacy and safety of galcanezumab for the prevention of episodic migraine: results of the EVOLVE-2 phase 3 randomized controlled clinical trial. Cephalalgia 2018; 38:1442.
- HC Detke et al. A phase 3 placebo-controlled study of galcanezumab in patients with chronic migraine: results from the 3-month double-blind treatment phase of the REGAIN study. Cephalalgia 2017; 37(1S):338.
- Q Zhang et al. Efficacy of galcanezumab in patients who failed to respond to preventives previously: results from EVOLVE-1, EVOLVE-2 and REGAIN studies. Neurology 2018; 90(15 Suppl):S20.004.
- A MaassenVanDenBrink et al. Wiping out CGRP: potential cardiovascular risks. Trends Pharmacol Sci 2016; 37:779.
- A Negro et al. Headache and pregnancy: a systematic review. J Headache Pain 2017; 18:106.
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.
Would you like to read the rest of this issue? Gain access below.
Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
- Print version published and mailed biweekly (26 issues/year)
- Unlimited online access to current and past issues (1988 - present)
- Mobile App for iOS, Android, and Kindle Fire
- FREE online per issue CME/CE
Purchase this issue:
Title: Issue 1559
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian
